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SummAry – Little is known about thyrotropin (TSh) and thyroid hormones in euthyroid 
hashimoto’s thyroiditis (hT), thus the aim was to investigate TSh and thyroid hormone economy 
in euthyroid hT and its relation to thyroid function. ninety-five patients with euthyroid hT with 
normal TSh and thyroid hormones on the last follow up between 2009 and 2011 were investigated. 
Previous observation period ranged from 1.5 to 4.8 (mean 2.8) years, and they had never been trea-
ted with levothyroxine. The results of TSh and thyroid hormones were compared with 210 healthy 
subjects and expressed as median (25%-75%). According to TSh value, the subjects were divided 
into quartiles: TSh 0.4-0.99 (1q), 1.0-1.99 (2q), 2.0-2.99 (3q) and 3.0-4.0 miu/L (4q). euthyro-
id hT patients had higher TSh (2.53 [1.79-3.14] vs.1.95 [1.24-2.72], p<0.001). T4 and T3 were 
not different. The distribution of TSh in hT patients was significantly shifted to the right; 71% 
of patients were in the 3q and 4q groups. When hT patients with higher TSh (3q and 4q) were 
compared with those with lower TSh (1q and 2q), significant differences emerged in TSh (3.01 
[2.48-3.48] vs.1.45 [1.07-1.71] miu/L), T4 (99.0 [88.2-112.0] vs.112.0 [105.0-122.0] nmol/L) and 
T3 (1.78 [1.48-2.05] vs. 2.10 [1.85-2.21] nmol/L; p<0.01). TPO values were similar in both groups. 
A gradually increasing proportion of euthyroid hT patients with at least one supranormal TSh 
during the observation period were found: 0% in 1q, 10% in 2q, 15% in 3q and 44% in 4q TSh 
group. euthyroid hT patients maintain euthyroidism only under strenuous TSh stimulation. The 
patients with high normal TSh are identified as those with a major risk of hypothyroidism in the 
near future. 
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Introduction 
hashimoto’s thyroiditis (hT), the most com-
mon cause of thyroid failure in the western world, is 
a slowly progressive disease, evolving from euthyroid-
ism to subclinical and overt hypothyroidism1. When 
these patients should be treated is a matter of contro-
versy. Little is known about thyrotropin (TSh) and 
thyroid hormone economy in euthyroid hashimoto’s 
thyroiditis, and the results in this study pointed to dif-
ference in TSh and thyroid hormones between these 
patients, particularly those with high normal TSh, 
and healthy subjects, suggesting that the disease is 
progressing even when TSh and thyroid hormones 
are still within the normal range.
Subjects and Methods
This study included 95 euthyroid patients with hT 
referred to Thyroid Center for regular follow up test-
ing between January 2009 and december 2011. The 
last follow up analysis, which was taken into account, 
showed normal values of TSh and thyroid hormones. 
Previous observation period ranged between 1.5 and 
4.8 (mean 2.8) years, and the patients had never been 
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treated with levothyroxine. This group was selected 
from a total number of 616 hT patients followed up 
in that period, 521 being treated with replacement 
therapy. The diagnosis of hT was confirmed by ul-
trasound, positive TPO autoantibody titer (>50 iu/
mL), and occasionally by fine-needle aspiration biopsy 
when hypertrophic thyroid nodules required morpho-
logical analysis.
According to their TSh values, euthyroid hT pa-
tients were divided into quartiles: TSh=0.4-0.99 (1 
quartile [q]), TSh=1.0-1.99 (2q), TSh=2.0-2.99 (3q) 
and TSh=3.0-4.0 miu (4q).
data from euthyroid hT patients were compared 
with those obtained from 210 healthy control subjects 
recruited from persons admitted to our outpatient 
clinic for investigation of thyroid function. There was 
no history or signs of thyroid disease, TSh and thy-
roid hormones were normal, and TPO was negative 
(<50 iu/mL). due to the small number of male sub-
jects in both hT patient and control groups (n=6 and 
n=13, respectively), only females were included. The 
subjects from either hT or control group did not suf-
fer from any (other) endocrine disease and were free 
from medication that could affect TSh-thyroid hor-
mone secretion.
Blood samples were taken in fasting condition be-
tween 7.30 an 9.00 a.m., and TSh, thyroid hormones 
and TPO determined on immulite 1000 analyzer. nor-
mal values for TSh, T4, and T3 were 0.4-4.0 miu/L, 
65-165 nmol/L and 1.1-2.9 nmol/L, respectively.
Statistical analysis included mann-Whitney rank 
sum test for nonparametric data and Fisher’s exact 
test; p<0.05 was considered significant.
Results
Figure 1 shows distribution of TSh values in 
euthyroid hT patients and healthy subjects. unlike 
normal distribution in controls, results in euthyroid 
patients were markedly shifted toward higher values. 
Only 3% of patients had TSh <1.0 miu/L (1q TSh 
group) in comparison with 16% of healthy subjects 
(p<0.001), while 35% of euthyroid hT patients and 






median 25%-75% median 25%-75%
Age (years) 46.0* 35.0-60.0 41.0 29.0-58.7
TSh (miu/L) 2.53** 1.79-3.14 1.95 1.24-2.72
T4 (nmol/L) 104.5ns 91.5-116.0 104.0 92.3-119.5
T3 (nmol/L) 1.98ns 1.68-2.13 1.82 1.24-2.72
T4/TSh 36.9** 29.4-61.4 54.8 37.5-99.0
*p<0.05; **p<0.001; nsnonsignificant
Table 1. Age, TSH, T4, T3 and T4/TSH ratio in euthyroid Hashimoto’s 
thyroiditis patients and control subjects
*p<0.001; nsnonsignificant; total number of hT patients was 3 in 1q, 
24 in 2q, 31 in 3q and 37 in 4q TSh. in controls, total numbers were 
31, 76, 72 and 31, respectively.
Fig. 1. Different TSH distribution in patients with eu-
thyroid Hashimoto’s thyroiditis (HT) and healthy control 
subjects. 
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euthyroid hT patients were older, with a signifi-
cantly higher serum TSh than controls. Serum T4 
and T3 were not different (Table 1). When data from 
euthyroid hT patients with serum TSh >2.0 miu/L 
(3q and 4q TSh groups) were compared with those 
with serum TSh <2.0 (1q and 2 q TSh groups), sig-
nificant differences emerged in TSh, T4 and T3 val-
ues (Table 2). The values of TSh in 3q and 4q groups 
were significantly higher and those of T4 and T3 low-
er than in 1q and 2q TSh groups. The T4/TSh ratio 
in 3q and 4q TSh groups was also significantly lower 
than in hT patients with 1q and 2q TSh. The values 
of TPO antibody titer were similar in both groups.
during the observation period, some euthyroid 
hT patients showed at least one supranormal (4.1-6.5 
miu/L) TSh value. The percentage of these patients 
increased in relation to their TSh value on the last 
follow up: none in 1q, 10% in 2q, 15% in 3q and 44% 
in 4q TSh group.
Discussion
The distribution of TSh in euthyroid hT patients 
was shifted toward higher values. Only three patients 
had low normal (1q) TSh and more than 70% showed 
3q and 4q TSh. in fact, the distribution curve in eu-
thyroid hT patients was similar to that in properly 
treated (TSh=0.4-4.0 miu/L)) hypothyroid patients 
(unpublished data). Age could influence TSh values, 
especially in the upper end of the normal range; how-
ever, although hT patients in general were older than 
controls, there was no difference between those with 
lower and higher normal TSh. 
Significant difference in TSh value was found not 
only between euthyroid hT patients and controls, 
but also between patients with lower (1q and 2q) and 
higher (3q and 4q) normal TSh. higher TSh, lower 
T4 and T3 and low T4/TSh ratio reflected borderline 
thyroid function with diminished TSh suppressibili-
ty in the latter group. There was no difference in TPO 
between these two groups, and probably the duration 
of the disease is the clue for these changes. unfor-
tunately, patients are seen relatively late due to some 
nonspecific symptoms, or are detected accidentally, 
and the beginning of the disease is hidden in patient 
history.
These patients manage to maintain euthyroid-
ism under strenuous TSh stimulation, but in many 
of them, thyroid functions actually balance between 
euthyroid and subclinically hypothyroid, with occa-
sional mildly elevated TSh.
many euthyroid hT patients have 4q TSh. This 
implies that the other way around is also plausible; 
subjects with TSh close to the upper normal limit are 
probably not healthy and have euthyroid hT. TSh 
upper reference limit may be skewed by the occult 
thyroid dysfunction2 and determination of TPO is 
mandatory.
Whether euthyroid hT patients should be treated 
is controversial. The situation is complicated by the 
proposal of a narrower normal TSh range with the 
upper limit of 2.5 miu/L3, supported by some4,5 and 
TSh 0.4-1.99 miu/L 
(n=28)
TSh 2.0-4.0 miu/L 
(n=67)
median 25%-75% median 25%-75%
Age (years) 46.0 16.0-37.0 48.0ns 37.0-60.0
TSh (miu/L) 1.45 1.075-1.71 3.015** 2.48-3.48
T4 (nmol/L) 112.0 105.0-122.0 99.0 ** 88.2-112.0
T3 (nmol/L) 2.10 1.85-2.21 1.78* 1.48-2.05
T4/TSh ratio 78.2 72.4-103.4 33.2** 26.0-40.3
TPO-Ab (iu/mL) 226.5 125,0-600.0 285.0ns 185.0-430.0
*p<0.01; **p<0.001; nsnonsignificant 
Table 2. Comparison of age, TSH, T4, T3, T4/TSH ratio and TPO-Ab be-
tween two groups of euthyroid Hashimoto’s thyroiditis patients (with lower and 
higher normal serum TSH) 
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opposed by others6,7. A meta-analysis provided no 
convincing evidence that the treatment of subclinical 
hypothyroidism is generally justified8. On the other 
hand, it has been reported recently that patients with 
subclinical hypothyroidism improved their quality of 
life following levothyroxine administration9. how-
ever, many subclinically hypothyroid patients are not 
treated with replacement therapy6, let alone should 
be those with upper normal TSh. The goal of treat-
ment of euthyroid hT patients should be different, 
aimed at slowing down the autoimmune destructive 
process. A short-term levothyroxine treatment has 
been proposed to postpone hypothyroidism10-12, and 
levothyroxine decreased TPO antibodies in euthyroid 
hT patients13 and lowered the chance for miscarriage 
and premature delivery in pregnant women with eu-
thyroid hT14. Or euthyroid hT patients could be the 
best candidates for selenium administration trial15 to 
diminish the autoimmune/inflammatory damages to 
thyrocytes via glutathione peroxidase. in addition, ei-
ther or both compounds are found to improve hemo-
static disturbances in euthyroid hT patients16. 
in any case, euthyroid hT patients with high nor-
mal TSh (especially 4q group) are identified as those 
with a major risk of developing hypothyroidism in the 
near future and even if not treated, they should be 
carefully observed.
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Sažetak
TireOTrOPin i hOrmOni šTiTnJAče u euTireOidnOm hAShimOTOVu TireOidiTiSu
D. Solter i M. Solter
malo je poznato o vrijednostima tireoptropina (TSh) i hormona štitnjače u eutireoidnom hashimotovu tireoiditisu 
(hT) te je cilj bio istražiti razinu TSh i hormona štitnjače u hT i njihov odnos prema funkciji štitnjače. ispitano je 95 
bolesnika s eutireoidnim hT s normalnim TSh i hormonima štitnjače na posljednjoj kontroli između 2009. i 2011. 
godine. Prethodno razdoblje promatranja variralo je od 1,5 do 4,8 (u prosjeku 2,8) godina, bolesnici nisu nikada liječeni 
levotiroksinom. rezultati TSh i hormona štitnjače uspoređeni su s onima u 210 zdravih osoba i prikazani kao medijan 
(25%-75%). Prema vrijednosti TSh ispitanici su podijeljeni u kvartile: TSh 0,4-0,99 (1q), 1,0-1,99 (2q), 2,0-2,99 (3q) i 
3,0-4,0 miu/L (4q). eutireoidni bolesnici s hT imali su viši TSh (2,53 [1,79-3,14] prema 1,95 [1,24-2,72], p<0,001). T4 
i T3 se nisu razlikovali. raspodjela TSh u hT izrazito je pomaknuta udesno. ukupno je 71% bolesnika bilo u skupini 
3q i 4q. Kada se usporede hT bolesnici s višim (3q i 4q) i nižim TSh (1q i 2q) nalaze se značajne razlike u TSh (3,01 
[2,48-3,48] prema 1,45 [1,07-1,71] miu/L), T4 (99,0 [88,2-112,0] prema 112,0 [105,0-122,0] nmol/L) i T3 (1,78 [1,48-
2,05] prema 2,10 [1,85-2,21] nmol/L; p<0,01). Vrijednosti TPO bile su slične u obje skupine hT bolesnika. Opažen je 
postupni porast postotka eutireoidnih hT bolesnika s najmanje jednom povišenom vrijednošću TSh tijekom razdoblja 
promatranja: 0% u skupini 1q, 10% u 2q, 15% in 3q i 44% u skupini 4q. eutireoidni bolesnici s hT održavaju eutireozu 
jedino uz povećanu stimulaciju pomoću TSh. Bolesnici s visoko normalnim TSh imaju najveći rizik nastupa hipotireoze 
u bliskoj budućnosti. 
Ključne riječi: Hashimotova bolest; Štitnjača, bolesti; TSH; Hormoni štitnjače
